{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:37:57Z","timestamp":1768927077298,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012670","name":"Dysimmune Diseases Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008476","name":"University of California-Irvine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.intimp.2020.106385","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T10:41:08Z","timestamp":1584009668000},"page":"106385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Rationale for including intravenous immunoglobulin in the multidrug protocol of curative treatment of pemphigus vulgaris and development of an assay predicting disease relapse"],"prefix":"10.1016","volume":"82","author":[{"given":"Sergei A.","family":"Grando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rigas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Chernyavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0030-4220(74)90365-X","article-title":"Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion","volume":"38","author":"Pisanti","year":"1974","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106385_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-4632.2004.02501.x","article-title":"Pemphigus: analysis of 1209 cases","volume":"44","author":"Chams-Davatchi","year":"2005","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106385_b0015","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases","volume":"6","author":"Daoud","year":"2006","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ijd.14143","volume":"58","author":"Grando","year":"2019","journal-title":"Int. J. Dermatol."},{"issue":"10083","key":"10.1016\/j.intimp.2020.106385_b0025","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"French study group on autoimmune bullous skin, First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2020.106385_b0030","article-title":"Comparison of real costs in the French healthcare system in newly diagnosed pemphigus patients: first-line treatment with rituximab versus standard corticosteroid regimen. Data of a national multicentre trial","author":"Hebert","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2020.106385_b0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2020.106385_b0040","series-title":"Biologic and Systemic Agents in Dermatology","first-page":"401","article-title":"Role of intravenous immunoglobulin in dermatologic disorders","author":"Amber","year":"2018"},{"issue":"5","key":"10.1016\/j.intimp.2020.106385_b0045","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaad.2008.01.007","article-title":"Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus","volume":"58","author":"Czernik","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/mjd.2002.122735","article-title":"Treatment of pemphigus with intravenous immunoglobulin","volume":"47","author":"Bystryn","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/08916934.2011.606452","article-title":"Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update","volume":"45","author":"Czernik","year":"2012","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/08916934.2011.606444","article-title":"Pemphigus autoimmunity: hypotheses and realities","volume":"45","author":"Grando","year":"2012","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/1523-1747.ep12518278","article-title":"Methylprednisolone inhibits pemphigus acantholysis in skin cultures","volume":"81","author":"Swanson","year":"1983","journal-title":"J, Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106385_b0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00917138","article-title":"Acantholysis produced in vitro with pemphigus serum: hydrocortisone inhibits acantholysis, while dapsone and 6-mercaptopurine do not inhibit acantholysis","volume":"4","author":"Jeffes","year":"1984","journal-title":"J. Clin. Lab. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0075","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1074\/jbc.M309000200","article-title":"Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes","volume":"279","author":"Nguyen","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2020.106385_b0080","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/archderm.1988.01670020054017","article-title":"Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine","volume":"124","author":"Fine","year":"1988","journal-title":"Arch. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106385_b0085","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/archderm.1996.03890360021005","article-title":"Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids","volume":"132","author":"Werth","year":"1996","journal-title":"Arch. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106385_b0090","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archderm.1996.03890360091015","article-title":"Pulse glucocorticoid therapy. The 'big shot' revisited","volume":"132","author":"Roujeau","year":"1996","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.intimp.2020.106385_b0095","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-4362.1995.tb04450.x","article-title":"Steroid-pulse therapy in pemphigus vulgaris long term follow-up","volume":"34","author":"Chryssomallis","year":"1995","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106385_b0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4103\/0019-5154.74536","article-title":"Assessing the autoantibody levels in relation to disease severity and therapy response in pemphigus patients","volume":"55","author":"Aksu","year":"2010","journal-title":"Indian J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106385_b0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/archderm.1976.01630310024005","article-title":"Pemphigus: a 20-year review of 107 patients treated with corticosteroids","volume":"112","author":"Rosenberg","year":"1976","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2020.106385_b0110","doi-asserted-by":"crossref","unstructured":"W.F. Lever, Pemphigus and Pemphigoid, Charles C. Thomas, Springfield, 1965, pp. 1\u2013266.","DOI":"10.1001\/jama.1965.03080160086045"},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archderm.1984.01650370050009","article-title":"Treatment of pemphigus vulgaris: results obtained in 84 patients between 1961 and 1982","volume":"120","author":"Lever","year":"1984","journal-title":"Arch. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2014.04.040","article-title":"Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents","volume":"71","author":"McCarty","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"39","key":"10.1016\/j.intimp.2020.106385_b0125","doi-asserted-by":"crossref","first-page":"23826","DOI":"10.1074\/jbc.M115.668061","article-title":"Critical Role of the Neonatal Fc Receptor (FcRn) in the pathogenic action of antimitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris","volume":"290","author":"Chen","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.intimp.2020.106385_b0130","doi-asserted-by":"crossref","first-page":"16916","DOI":"10.1074\/jbc.M113.472100","article-title":"Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies","volume":"288","author":"Kalantari-Dehaghi","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2020.106385_b0135","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1074\/jbc.M109.081570","article-title":"Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology","volume":"285","author":"Marchenko","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.intimp.2020.106385_b0140","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/archderm.1988.01670110019004","article-title":"Controlled study of plasma exchange in pemphigus","volume":"124","author":"Guillaume","year":"1988","journal-title":"Arch. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0190-9622(90)70004-2","article-title":"Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies","volume":"22","author":"Tan-Lim","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2020.106385_b0150","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/08916930600972016","article-title":"IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris","volume":"39","author":"Bystryn","year":"2006","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0155","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2010.04.001","article-title":"Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies","volume":"64","author":"Lolis","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106385_b0160","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2020.106385_b0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00912.x","article-title":"Mechanisms that determine plasma cell lifespan and the duration of humoral immunity","volume":"236","author":"Amanna","year":"2010","journal-title":"Immunol. Rev."},{"issue":"5601","key":"10.1016\/j.intimp.2020.106385_b0170","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.intimp.2020.106385_b0175","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fimmu.2018.00779","article-title":"Humoral epitope spreading in autoimmune bullous diseases","volume":"9","author":"Didona","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106385_b0180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.12073","article-title":"Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris","volume":"38","author":"Sharma","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106385_b0185","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/archderm.1996.03890360112026","article-title":"Curative treatment for pemphigus","volume":"132","author":"Pasricha","year":"1996","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2020.106385_b0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/exd.13106","article-title":"Monopathogenic vs. multipathogenic explanations of pemphigus pathophysiology","author":"Ahmed","year":"2016","journal-title":"Exp. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2020.106385_b0195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s004030050347","article-title":"Relationship between keratinocyte adhesion and death: anoikis in acantholytic diseases","volume":"290","author":"Gniadecki","year":"1998","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1523-1747.2003.12014.x","article-title":"Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8","volume":"120","author":"Puviani","year":"2003","journal-title":"J. Invest. Dermatol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2020.106385_b0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.febslet.2004.03.107","article-title":"Pemphigus vulgaris autoantibodies induce apoptosis in HaCaT keratinocytes","volume":"566","author":"Pelacho","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.intimp.2020.106385_b0210","series-title":"The Decade of Autoimmunity","first-page":"606","article-title":"Pemphigus an autoimmune disease of the skin: cell-cell separation versus membrane signaling and apoptosis in acantholysis","author":"Milner","year":"1999"},{"key":"10.1016\/j.intimp.2020.106385_b0215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1196\/annals.1313.040","article-title":"The interaction of pemphigus autoimmunoglobulins with epidermal cells: activation of the fas apoptotic pathway and the use of caspase activity for pathogenicity tests of pemphigus patients","volume":"1050","author":"Frusic-Zlotkin","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2020.106385_b0220","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1468-3083.2009.03162.x","article-title":"The final destiny of acantholytic cells in pemphigus is Fas mediated","volume":"23","author":"Pacheco-Tovar","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106385_b0225","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0002-9440(10)61239-4","article-title":"Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus","volume":"167","author":"Arredondo","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106385_b0230","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1074\/jbc.RA118.006743","article-title":"Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris","volume":"294","author":"Chernyavsky","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2020.106385_b0235","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-desmoglein antibodies in patients with pemphigus vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106385_b0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D36PV5W474","article-title":"Acetylcholine receptor antibodies in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up","volume":"18","author":"Tirado-Sanchez","year":"2012","journal-title":"Dermatol. Online J."},{"issue":"5","key":"10.1016\/j.intimp.2020.106385_b0245","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaad.2016.11.039","article-title":"Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus","volume":"76","author":"Lakshmi","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106385_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031361","article-title":"Mitochondria express alpha7 nicotinic acetylcholine receptors to regulate Ca2+ accumulation and cytochrome c release: study on isolated mitochondria","volume":"7","author":"Gergalova","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.106385_b0255","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.biocel.2014.05.030","article-title":"Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction","volume":"53C","author":"Lykhmus","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0260","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11062-011-9203-7","article-title":"Possible influence of a7 nicotinic acetylcholine receptor activation in the mitochondrial membrane on apoptosis development","volume":"43","author":"Gergalova","year":"2011","journal-title":"Neurophysiology"},{"issue":"5","key":"10.1016\/j.intimp.2020.106385_b0265","first-page":"13","article-title":"Nicotine effects on mitochondria membrane potential: participation of nicotinic acetylcholine receptors","volume":"83","author":"Gergalova","year":"2011","journal-title":"Ukr. Biokhim. Zh."},{"issue":"21\u201322","key":"10.1016\/j.intimp.2020.106385_b0270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.lfs.2012.02.005","article-title":"Intracellular localization of nicotinic acetylcholine receptors in human cell lines","volume":"91","author":"Kalashnyk","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2020.106385_b0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biocel.2014.01.001","article-title":"alpha7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways","volume":"49","author":"Gergalova","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.intimp.2020.106385_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106149","article-title":"Mechanisms of synergy of autoantibodies to M3 muscarinic acetylcholine receptor and secretory pathway Ca(2+)\/Mn(2+)-ATPase isoform 1 in patients with non-desmoglein pemphigus vulgaris","volume":"80","author":"Chernyavsky","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"4A","key":"10.1016\/j.intimp.2020.106385_b0285","first-page":"2657","article-title":"Synthetic retinoid CD437 induces apoptosis of esophageal squamous HET-1A cells through the caspase-3-dependent pathway","volume":"21","author":"Wan","year":"2001","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0290","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2249.2010.04265.x","article-title":"Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris","volume":"162","author":"Mimouni","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106385_b0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/B:APPT.0000018795.05766.1f","article-title":"Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins","volume":"9","author":"Wang","year":"2004","journal-title":"Apoptosis"},{"issue":"18","key":"10.1016\/j.intimp.2020.106385_b0300","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1074\/jbc.M808204200","article-title":"Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2020.106385_b0305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-4362.2001.01083.x","article-title":"TNFalpha and IL-6 are mediators in the blistering process of pemphigus","volume":"40","author":"Lopez-Robles","year":"2001","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106385_b0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.intimp.2015.04.046","article-title":"Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis","volume":"29","author":"Chernyavsky","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106385_b0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4161\/cbt.5.5.2601","article-title":"Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells","volume":"5","author":"Arredondo","year":"2006","journal-title":"Cancer Biol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920300230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920300230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:34:37Z","timestamp":1727454877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920300230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":63,"alternative-id":["S1567576920300230"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106385","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for including intravenous immunoglobulin in the multidrug protocol of curative treatment of pemphigus vulgaris and development of an assay predicting disease relapse","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106385"}}